Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | Targetable alterations in bladder cancer

Siamak Daneshmand • 16 Feb 2023
GU Cancers 2023
Bladder Cancer Genitourinary Cancer

Siamak Daneshmand, MD, University of Southern California, Los Angeles, CA, talks on targetable alterations for bladder cancer, focusing on FGFR3. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Siamak Daneshmand

0:43
The emerging role of gene therapies for bladder cancer
Siamak Daneshmand • 25 Jan 2024
0:59
Nadofaragene firadenovec: an adenoviral vector-based gene therapy for bladder cancer
Siamak Daneshmand • 25 Jan 2024
1:56
Real-world evaluation of nadofaragene firadenovec in BCG-Unresponsive NMIBC
Siamak Daneshmand • 25 Jan 2024
2:36
Advancements in surgery for GU cancers
Siamak Daneshmand • 16 Feb 2023

Related Videos

10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals